Jericho Oil Exercises Option to Increase STACK Joint Venture Ownership
Jan 03, 2018 21:06 pm UTC| Business
TULSA, Okla.and VANCOUVER, British Columbia, Jan. 03, 2018 -- Jericho Oil Corporation (“Jericho”) (TSX-V:JCO) (OTC PINK:JROOF) announces that it has fully exercised its option to increase its ownership in its Oklahoma...
SMART Global Holdings to Participate in 20th Annual Needham Growth Conference
Jan 03, 2018 21:06 pm UTC| Business
NEWARK, Calif., Jan. 03, 2018 -- SMART Global Holdings, Inc. (“SMART”) (NASDAQ:SGH), the parent company of SMART Modular Technologies, Inc., today announced that it will participate in the following investor event: ...
GBT to Present at the 36th Annual J.P. Morgan Healthcare Conference
Jan 03, 2018 21:06 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ:GBT) today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10,...
Five Prime Therapeutics to Present at 36th Annual J.P. Morgan Healthcare Conference
Jan 03, 2018 21:06 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron...
Jan 03, 2018 21:05 pm UTC| Business
Supplemental NDA for ITP to be submitted in the second half of 2018 Phase 3 Clinical Trial for CIT to begin in the second quarter of 2018 DURHAM, N.C., Jan. 03, 2018 -- Following two separate meetings with the U.S....
Zai Lab Limited to present at the 36th Annual J.P. Morgan Healthcare Conference
Jan 03, 2018 21:05 pm UTC| Business
SHANGHAI, China, Jan. 03, 2018 -- Zai Lab Limited (NASDAQ:ZLAB), a Shanghai-based innovative biopharmaceutical company, today announced that Chief Executive Officer, Samantha Du, will present at the 36th Annual J.P....
Five Prime Therapeutics Submits Investigational New Drug Application for Novel B7-H4 Antibody FPA150
Jan 03, 2018 21:05 pm UTC| Business
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced the December...